es generated from exenatide
may be affected by competition, unexpected new data, technical issues,
clinical trials not confirming previous results or predicting future
results, label expansion requests not being submitted in a timely manner or
receiving regulatory approval, or manufacturing and supply issues. The
potential for exenatide may also be affected by government and commercial
reimbursement and pricing decisions, the pace of market acceptance, or
scientific, regulatory and other issues and risks inherent in the
commercialization of pharmaceutical products. These and additional risks
and uncertainties are described more fully in Amylin and Lilly's most
recently filed United States Securities Exchange Commission documents such
as their Quarterly Reports on Form 10-Q. Amylin and Lilly undertake no duty
to update these forward-looking statements.
P-LLY
REFERENCES
1 Bunck MC, Diamant MA, Corner EB, Malloy JL, Shaginian RM, Deng W,
Kendall DM, Taskinen MR, Smith U, Yki-Jarvinen H, and Heine RJ. One
year treatment with exenatide improves beta-cell function and glycaemic
control in metformin treated type 2 diabetes patients. Control/Tracking
Number: A-07-175-EASD.
2 "Definition of C-peptide." MedicineNet.com. Available at
http://www.medterms.com/script/main/art.asp?articlekey=12467. Accessed
July 25, 2007.
3 Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P,
Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment
of insulin secretion and insulin sensitivity using a hyperglycemia
clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382.
4 The International Diabetes Federation Diabetes Atlas. Available at:
http://www.idf.org/home/index.cfm
'/>"/>
SOURCE Eli Lilly and Company Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer2.
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs3.
Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results4.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis5.
Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures6.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis7.
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis8.
Protox Announces Positive Clinical Data from Prostate Cancer Study9.
International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis10.
New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility11.
Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea